Revenue Update on Atrion Corporation(NASDAQ:ATRI)

Atrion Corporation(NASDAQ:ATRI) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during After-hours on Aug 9, 2016. Earnings per share were $4.02.

Atrion Corporation (ATRI) shares turned negative on Wednesdays trading session with the shares closing down -0.29 points or -0.06% at a volume of 6,762. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $452. The peak price level was also seen at $452 while the days lowest was $440.62. Finally the shares closed at $446.28. The 52-week high of the shares is $490.45 while the 52-week low is $343.4999. According to the latest information available, the market cap of the company is $814 M.

Several Insider Transactions has been reported to the SEC. On Jun 24, 2016, Emile A Battat (Chairman) sold 12 shares at $432.00 per share price.Also, On Jun 20, 2016, Jeffery Strickland (CFO) sold 1,000 shares at $425.70 per share price.On Aug 27, 2015, Ronald Nicholas Spaulding (director) sold 500 shares at $375.90 per share price, according to the Form-4 filing with the securities and exchange commission.

Atrion Corporation (Atrion) develops and manufactures products primarily for medical applications. The Company’s medical products range from fluid delivery devices to ophthalmic and cardiovascular products. The Company’s fluid delivery products include valves that promote infection control and needle safety. The Company has developed a variety of luer syringe check valves and one-way valves designed to fill hold and release controlled amounts of fluids or gasses on demand for use in various intubation catheter and other applications. The Company also makes tubing clamps in a variety of materials and colors that are compatible with various grades of tubing and sterilization processes and produce specialized intravenous sets for use in numerous applications including anesthesia and oncology. The Company’s principal cardiovascular product is the Myocardial Protection System (MPS2) a technology that delivers essential fluids and medications to the heart during open-heart surgery.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Atrion Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on Atrion Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.